Keren Zhou, MD, is research director in the Institute of Endocrinology & Metabolism at Cleveland Clinic, Cleveland, Ohio. Her specialty interests include diabetes, with an emphasis on diabetes technology, as well as oncology-related care, metabolic bone disease and general endocrinology.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a newer class of medications for individuals with type 2 diabetes. While their blood-sugar-lowering ability is only moderate, other...
